Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire EyeBio Limited, a prominent ... Read More
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have ... Read More
Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the ... Read More
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This ... Read More
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial. The trial ... Read More
Top North Georgia eye clinics merge to form North Georgia Eye Associates
Gainesville Eye Associates and North Georgia Eye Clinic, two of the major ophthalmology practices in North Georgia, have combined their operations to form North Georgia ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Health Network One acquires managed eye care provider Premier Eye Care
Health Network One, a portfolio company of H.I.G. Capital, has acquired US-based managed eye care provider Premier Eye Care for an undisclosed price. Established in ... Read More
SPARC signs licensing deal with Visiox for two ophthalmic drug candidates
Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide rights (except for India and Greater China) ... Read More